{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:21:21Z","timestamp":1794543681505,"version":"4.9.1"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Crown Bioscience, Inc."}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Drug combination therapy is a promising strategy for treating cancer; however, its efficacy and synergy require rigorous evaluation in preclinical studies before going to clinical trials. Existing methods have limited power to detect synergy in animal studies. Here, we introduce a novel approach to assess in vivo drug synergy with high sensitivity and low false discovery rate. It can accurately estimate combination index and synergy score under the Bliss independence model and the highest single agent (HSA) model without any assumption on tumor growth kinetics, study duration, data completeness and balance for tumor volume measurement. We show that our method can effectively validate in vitro drug synergy discovered from cell line assays in in vivo xenograft experiments, and can help to elucidate the mechanism of action for immune checkpoint inhibitors in syngeneic mouse models by combining an anti-PD-1 antibody and several tumor-infiltrating leukocytes depletion treatments. We provide a unified view of in vitro and in vivo synergy by presenting a parallelism between the fixed-dose in vitro and the 4-group in vivo combination studies, so they can be better designed, analyzed, and compared. We emphasize that combination index, when defined here via relative survival of tumor cells, is both dose and time dependent, and give guidelines on designing informative in vivo combination studies. We explain how to interpret and apply Bliss and HSA synergies. Finally, we provide an open-source software package named invivoSyn that enables automated analysis of in vivo synergy using our method and several other existing methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This work presents a general solution to reliably determine in vivo drug synergy in single-dose 4-group animal combination studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0243","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T08:13:38Z","timestamp":1697184818000},"page":"2146-2157","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Statistical Assessment of Drug Synergy from\n                    <i>In Vivo<\/i>\n                    Combination Studies Using Mouse Tumor Models"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3113-7400","authenticated-orcid":true,"given":"Binchen","family":"Mao","sequence":"first","affiliation":[{"name":"1Crown Bioscience Inc., Suzhou, Jiangsu, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-0457","authenticated-orcid":true,"given":"Sheng","family":"Guo","sequence":"additional","affiliation":[{"name":"1Crown Bioscience Inc., Suzhou, Jiangsu, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"2023102314093378000_bib1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Al-Lazikani","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2023102314093378000_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and conquer: challenges for targeted therapy combinations in early phase trials","volume":"14","author":"Lopez","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2023102314093378000_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"2023102314093378000_bib4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks","year":"2022","journal-title":"Nature"},{"key":"2023102314093378000_bib5","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1158\/0008-5472.CAN-17-0489","article-title":"The National Cancer Institute ALMANAC: a comprehensive screening resource for the detection of anticancer drug pairs with enhanced therapeutic activity","volume":"77","author":"Holbeck","year":"2017","journal-title":"Cancer Res"},{"key":"2023102314093378000_bib6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-15-0843","article-title":"An unbiased oncology compound screen to identify novel combination strategies","volume":"15","author":"O'Neil","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2023102314093378000_bib7","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1038\/s41467-019-09799-2","article-title":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","volume":"10","author":"Menden","year":"2019","journal-title":"Nat Commun"},{"key":"2023102314093378000_bib8","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2023102314093378000_bib9","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2023102314093378000_bib10","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"2023102314093378000_bib11","doi-asserted-by":"crossref","first-page":"25523","DOI":"10.1038\/srep25523","article-title":"BRAID: a unifying paradigm for the analysis of combined drug action","volume":"6","author":"Twarog","year":"2016","journal-title":"Sci Rep"},{"key":"2023102314093378000_bib12","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1093\/bioinformatics\/btaa102","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"36","author":"Ianevski","year":"2020","journal-title":"Bioinformatics"},{"key":"2023102314093378000_bib13","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1038\/s41467-021-24789-z","article-title":"MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery","volume":"12","author":"Wooten","year":"2021","journal-title":"Nat Commun"},{"key":"2023102314093378000_bib14","first-page":"285","article-title":"The problem of synergism and antagonism of combined drugs","volume":"3","author":"Loewe","year":"1953","journal-title":"Arzneimittelforschung"},{"key":"2023102314093378000_bib15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"2023102314093378000_bib16","first-page":"93","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol Rev"},{"key":"2023102314093378000_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"key":"2023102314093378000_bib18","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","article-title":"Quantifying drug combination synergy along potency and efficacy axes","volume":"8","author":"Meyer","year":"2019","journal-title":"Cell Syst"},{"key":"2023102314093378000_bib19","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.drudis.2019.09.002","article-title":"Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls","volume":"24","author":"Vlot","year":"2019","journal-title":"Drug Discov Today"},{"key":"2023102314093378000_bib20","doi-asserted-by":"crossref","first-page":"e1006752","DOI":"10.1371\/journal.pcbi.1006752","article-title":"Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer","volume":"15","author":"Malyutina","year":"2019","journal-title":"PLoS Comput Biol"},{"key":"2023102314093378000_bib21","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.1158\/1078-0432.CCR-04-1087","article-title":"Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses","volume":"10","author":"Zhao","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2023102314093378000_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"2023102314093378000_bib23","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41598-020-58438-0","article-title":"Identification of synergistic drug combinations using breast cancer patient-derived xenografts","volume":"10","author":"Turner","year":"2020","journal-title":"Sci Rep"},{"key":"2023102314093378000_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10543406.2011.556285","article-title":"Assessing interactions for fixed-dose drug combinations in tumor xenograft studies","volume":"22","author":"Wu","year":"2012","journal-title":"J Biopharm Stat"},{"key":"2023102314093378000_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pst.1559","article-title":"Assessing interactions for fixed-dose drug combinations in subcutaneous tumor xenograft studies","volume":"12","author":"Wu","year":"2013","journal-title":"Pharm Stat"},{"key":"2023102314093378000_bib26","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/pst.1952","article-title":"Detecting bliss synergy in in vivo combination studies with a tumor kinetic model","volume":"18","author":"Zhao","year":"2019","journal-title":"Pharm Stat"},{"key":"2023102314093378000_bib27","doi-asserted-by":"crossref","first-page":"12984","DOI":"10.1038\/s41598-022-16933-6","article-title":"CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts","volume":"12","author":"Huang","year":"2022","journal-title":"Sci Rep"},{"key":"2023102314093378000_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/09553000903419304","article-title":"Three endpoints of in vivo tumour radiobiology and their statistical estimation","volume":"86","author":"Demidenko","year":"2010","journal-title":"Int J Radiat Biol"},{"key":"2023102314093378000_bib29","doi-asserted-by":"crossref","first-page":"e0224137","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on Bliss definition of drugs independence","volume":"14","author":"Demidenko","year":"2019","journal-title":"PLoS One"},{"key":"2023102314093378000_bib30","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1158\/1078-0432.CCR-23-0488","article-title":"Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer","volume":"29","author":"Traphagen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2023102314093378000_bib31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1186\/s12885-019-5907-7","article-title":"The design, analysis and application of mouse clinical trials in oncology drug development","volume":"19","author":"Guo","year":"2019","journal-title":"BMC Cancer"},{"key":"2023102314093378000_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat Methods"},{"key":"2023102314093378000_bib33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nmeth.3852","article-title":"An unbiased metric of antiproliferative drug effect in vitro","volume":"13","author":"Harris","year":"2016","journal-title":"Nat Methods"},{"key":"2023102314093378000_bib34","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/bioinformatics\/btaa826","article-title":"Synergy: a Python library for calculating, analyzing and visualizing drug combination synergy","volume":"37","author":"Wooten","year":"2021","journal-title":"Bioinformatics"},{"key":"2023102314093378000_bib35","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1038\/s41598-022-07153-z","article-title":"Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment","volume":"12","author":"Jin","year":"2022","journal-title":"Sci Rep"},{"key":"2023102314093378000_bib36","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2023102314093378000_bib37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.synres.2016.06.001","article-title":"Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice","volume":"3","author":"Fu","year":"2016","journal-title":"Synergy"},{"key":"2023102314093378000_bib38","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3389\/fphar.2019.01384","article-title":"Additive dose response models: defining synergy","volume":"10","author":"Lederer","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0243\/3372625\/crc-23-0243.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/10\/2146\/3374524\/crc-23-0243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/10\/2146\/3374524\/crc-23-0243.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T10:10:10Z","timestamp":1698055810000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/10\/2146\/729692\/Statistical-Assessment-of-Drug-Synergy-from-In"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,23]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0243","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24421768.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421780.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421786.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421783.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421771","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421780","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421774","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421786","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421783","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421777.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421768","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421771.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421777","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24421774.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6893422.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6893422","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]}}}